Form 8-K Celldex Therapeutics, For: Apr 16
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq reaches record high close, AI stocks rally
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Cowen Downgrades Celldex Therapeutics (CLDX) to Market Perform
April 16, 2018 1:02 PM EDTCowen downgraded Celldex Therapeutics (NASDAQ: CLDX) from Outperform to Market Perform.
Analyst Boris Peaker commented, "CLDX announced this morning that glemb'a pivotal METRIC study in gpNMB+ TNBC failed to meet its primary PFS endpoint. All glembatumumab development, including checkpoint inhibitor combination in melanoma, will... More
Celldex Therapeutics (CLDX) PT Lowered to $2.50 at H.C. Wainwright
April 16, 2018 10:54 AM EDTH.C. Wainwright lowered its price target on Celldex Therapeutics (NASDAQ: CLDX) to $2.50 (from $10.00) while maintaining a Buy rating.
Analyst Joseph Pantginis commented, "This morning, Celldex announced that the Phase 2b METRIC Study of glembatumumab vedotin compared to Xeloda in patients with metastatic... More
Celldex (CLDX) Set to Open Lower By 49% After METRIC Study Fails
April 16, 2018 8:24 AM EDTCelldex (NASDAQ: CLDX) was set to open lower by 49% Monday morning after announcing its Phase 2b METRIC Study of glembatumumab vedotin compared to Xeloda in patients with metastatic triple-negative breast cancers that overexpress gpNMB failed to meet its primary endpoint.
... More